- •
Proton therapy is a form of external beam radiotherapy that has several key advantages over conventional photon (x-ray) radiotherapy.
- •
Unlike x-rays, protons deposit their maximum dose at a specific depth, with no exit dose to normal tissues, exploiting a phenomenon known as the Bragg peak.
- •
Lack of exit dose allows for delivery of a therapeutic radiation dose to tumors in challenging anatomic locations.
- •
Reduction in integral dose (low-dose bath) to normal tissues may reduce the risk of late
Proton Therapy
Section snippets
Key points
Expansion and use of single-room centers
Until recently, the costs associated with developing and operating a proton center have been a key drawback. Traditional multiroom centers—typically housing 4 to 5 proton treatment rooms—have cost between $100 million and 300 million to build, with estimated annual operating costs of $15 million to $25 million.18 These centers typically have required bread-and-butter cases—breast cancer and prostate cancer—to economically sustain the center and subsidize the rare, complex cancers most likely to
Key clinical areas of use
The National Comprehensive Cancer Network guidelines currently support the use of proton therapy in various scenarios across more than 40 distinct cancer types,23 and several clinical trials are currently randomizing patients to proton therapy versus x-ray radiotherapy (Table 1).20 The following sections highlight selected key disease sites in which proton therapy may offer key advantages over conventional radiotherapy.
Future directions for research and use
Future directions for in silico and in vivo research aim to improve the understanding of the physics and biology of proton therapy and how these differ versus those of conventional photon radiation. Specifically, learning exactly where the Bragg peak occurs has key clinical implications, because proton depth dose uncertainty currently requires strategies that involve either treating a margin of normal tissue to ensure tumor coverage or avoiding a margin of tissue to avoid a key organ at risk.
References (59)
- et al.
The radiobiology of proton therapy: challenges and opportunities around relative biological effectiveness
Clin Oncol (R Coll Radiol)
(2018) - et al.
Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors
Int J Radiat Oncol Biol Phys
(2002) - et al.
Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma
Int J Radiat Oncol Biol Phys
(2004) - et al.
Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival
Int J Radiat Oncol Biol Phys
(2016) - et al.
Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines
Blood
(2018) - et al.
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group
Int J Radiat Oncol Biol Phys
(2015) - et al.
Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group
Pract Radiat Oncol
(2015) - et al.
Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes
Int J Radiat Oncol Biol Phys
(2011) - et al.
Radiation-related treatment effects across the age spectrum: differences and similarities or what the old and young can learn from each other
Semin Radiat Oncol
(2010) - et al.
Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis
Radiother Oncol
(2015)
Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities
Int J Radiat Oncol Biol Phys
Proton facility economics: the importance of “simple” treatments
J Am Coll Radiol
Single-room proton radiation therapy systems: no small change
Int J Radiat Oncol Biol Phys
Proton facility economics: single-room centers
J Am Coll Radiol
Long-term health and social function in adult survivors of paediatric astrocytoma: a report from the Childhood Cancer Survivor Study
Eur J Cancer
Late effects of childhood cancer
Lancet
Cognitive and adaptive outcomes after proton radiation for pediatric patients with brain tumors
Int J Radiat Oncol Biol Phys
Evidence-based review on the use of proton therapy in lymphoma from the particle therapy cooperative group (PTCOG) lymphoma subcommittee
Int J Radiat Oncol Biol Phys
Proton therapy for locally advanced breast cancer: a systematic review of the literature
Cancer Treat Rev
Late gastrointestinal toxicities following radiation therapy for prostate cancer
Eur Urol
Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas
Adv Radiat Oncol
Eye retention after proton beam radiotherapy for uveal melanoma
Int J Radiat Oncol Biol Phys
Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique
Int J Radiat Oncol Biol Phys
Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas
Radiother Oncol
Proton therapy for head and neck cancer
Curr Treat Options Oncol
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Lancet Oncol
Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis
Int J Radiat Oncol Biol Phys
Reirradiation with proton therapy for recurrent gliomas
Int J Part Ther
Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes
Int J Radiat Oncol Biol Phys
Cited by (27)
Cancer Control, Toxicity, and Secondary Malignancy Risks of Proton Radiation Therapy for Stage I-IIB Testicular Seminoma
2023, Advances in Radiation OncologyEPR analysis of the dosimetric properties of sulfamic acid irradiated by different ionizing radiations for radiotherapy and hadrontherapy applications
2021, Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and AtomsCitation Excerpt :Nevertheless, especially X-ray treatment always suffers from the physically insurmountable radiation output dose after the tumor. This output dose of X-rays also presents challenges for tumors requiring high doses in anatomically sensitive areas, such as tumors at the base of the skull near the brain stem, cranial nerves and/or optical structures [1]. The recent focus is on protons as they promote the destruction of cancer cells with limited damage to surrounding healthy cells.
Mechanisms underlying FLASH radiotherapy, a novel way to enlarge the differential responses to ionizing radiation between normal and tumor tissues
2020, Radiation Medicine and ProtectionCitation Excerpt :The first way to achieve this goal is to deposit as much energy of ionizing radiation as possible in tumor region while avoiding irradiating normal tissue. Over the past decades, new advanced technologies, such as intensity-modulated radiotherapy,1 stereotactic body radiotherapy,2 proton and carbon particle radiotherapy,3,4 have transformed radiotherapy into a precise and powerful treatment regimen for cancer patients by improving the spatial dose delivery. Nevertheless, the treatment of radiation-resistant tumors is still restricted by the dose-limiting normal tissue complications.
Advances in Glioblastoma Therapy: An Update on Current Approaches
2023, Brain Sciences
Disclosure Statement: M.J. LaRiviere, P.M.G. Santos, C.E. Hill-Kayser: nothing to disclose. J.M. Metz: advisory boards for Varian, IBA, and Provision.